Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Search
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Across Cancer Types
Across Cancer Types
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Gastrointestinal Cancers
Gastrointestinal Cancers
Facing lung cancer
Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
Lung Cancer
Lung Cancer
Living With Cancer
Every cancer journey is unique. Listen to the first-hand experiences of people living with cancer.
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Dietary Advice for Specific Cancers
Learn more about dietary advice for specific cancers from Taking Cancer On Through Flavour
The Research Process
The Research Process
Cancer's Big 4
We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Transforming Cancer Care
Transforming cancer care requires a diversity of minds.
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
High Protein Diets for Cancer Patients
Learn more about the benefits of high protein diets for cancer patients from Taking Cancer On Through Flavour